Acquired Company

Silverback Therapeutics merged with ARS Pharmaceuticals to form ARS Pharmaceuticals, with ARS continuing as the surviving company and trading under the SPRY ticker; the merger was completed on November 8, 2022.

ARS Pharmaceuticals, Inc. (SPRY) is an innovative biopharmaceutical firm based in San Diego, California, specializing in the development of ARS-1, a groundbreaking intranasal epinephrine aerosol. Designed to provide rapid and effective relief for life-threatening allergic reactions, ARS-1 leverages proprietary absorption technology to enhance usability and access for patients. Committed to addressing critical public health needs, ARS Pharmaceuticals aims to redefine allergy management and solidify its position as a leader in the allergy treatment market. With a strong focus on patient-centric solutions, the company is well-positioned to make a substantial impact within the healthcare sector. Show more

Location: 11682 EL CAMINO REAL, SAN DIEGO, CA, UNITED STATES, 92130, San Diego, CA, 92130, USA | Website: https://ars-pharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

955.9M

52 Wk Range

$6.66 - $18.90

Previous Close

$9.67

Open

$9.87

Volume

1,151,350

Day Range

$9.70 - $10.05

Enterprise Value

812.9M

Cash

59.56M

Avg Qtr Burn

-47.05M

Insider Ownership

16.83%

Institutional Own.

89.35%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.